On Tuesday, the FDA approved Johnson & Johnson’s (NYSE:JNJ) supplemental New Drug Application for Spravato (esketamine) CIII ...

New Brunswick, NJ January 21, 2025 Johnson & Johnson ( NYSE:JNJ) has finally got its breakthrough depression treatment, ...

J&J on Tuesday said the green light makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least two oral antidepressants.

The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...

Johnson & Johnson announced the U.S. FDA approval of a supplemental New Drug Application for Spravato CIII nasal spray, making this ...

Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray, making ...

Johnson & Johnson (JNJ) stock in focus as FDA expands the label for its depression therapy Spravato (esketamine) allowing its ...

Mizuho Securities analyst Graig Suvannavejh has reiterated their bullish stance on AXSM stock, giving a Buy rating on January 15.Stay Ahead of ...

In 2024, the sale of antidepressant drugs in Russia increased by 20%, reaching 16.1 million packages by November, according ...

Ahmedabad: Breathlessness, a feeling of choking, sudden fear, insomnia, incessant crying without cause, persistent negative ...

In 2024, the sale of antidepressants in Russia reached a record level, increasing by 20 percent compared to the previous year ...

Enthea is proud to announce that it will be presenting at the upcoming Sequire Investor Summit 2025. The 2025 Edition of the Sequire Investor Summit is scheduled for January 21st-23rd, 2025, at ...